Aveanna Healthcare (AVAH) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
13 Aug, 2026Strategic vision and leadership
Focus on transforming homecare value through a diversified national platform serving pediatric, adult, and geriatric patients in 39 states.
Leadership team with deep industry experience, including CEO, CFO, and Principal Accounting Officer, all in roles since 2023.
Financial performance and guidance
2026 revenue guidance exceeds $2.68 billion, with a gross margin of 32.2% and adjusted EBITDA over $365 million.
Q2 2026 revenue grew 13.7% year-over-year to $670.5 million, with gross margin up 3.7% and adjusted EBITDA up 8%.
Free cash flow for 2026 reached $75.4 million, a $38.5 million improvement over 2025.
Liquidity as of July 2026 was $432.7 million, with $1.48 billion in variable rate debt and interest rate hedges in place.
Business segments and operational highlights
Private Duty Services: $2.18 billion net revenue, 294 locations, 46,000 patients, 26-28% gross margin, 5-6% organic growth.
Home Health & Hospice: $271 million net revenue, 82 locations, 15,400 patients, 50-52% gross margin, 8-10% organic growth.
Medical Solutions: $186 million net revenue, 31,100 patients, 42-44% gross margin, 8-10% organic growth.
Latest events from Aveanna Healthcare
- Q2 2026 revenue up 13.7%, net income up 49.1%, and full-year guidance raised.AVAH
Q2 2026 - Double-digit growth sustained by payer partnerships, acquisitions, and disciplined cost management.AVAH
Bank of America Home Care Conference - Accelerated growth and margin expansion driven by acquisitions, payer strategy, and financial discipline.AVAH
46th Annual William Blair Growth Stock Conference - Q1 2026 revenue rose 15.9% and adjusted EBITDA 25.2%, driven by value-based homecare growth.AVAH
Investor presentation - Q1 revenue and earnings surged, with raised guidance and a major pediatric care acquisition pending.AVAH
Q1 2026 - Double-digit revenue and profit growth in 2025, robust 2026 outlook, and major acquisition announced.AVAH
Q4 2025 - Raised 2025 guidance and strong Q3 results highlight scalable, value-based growth and margin stability.AVAH
44th Annual J.P. Morgan Healthcare Conference - Q2 revenue rose 7% to $505M, adjusted EBITDA up 27.3%, guidance raised for 2024.AVAH
Q2 2024 - Q1 2025 saw 14% revenue growth, 93% EBITDA rise, and raised full-year guidance.AVAH
Q1 2025